Advertisement

Topics

Ensysce Biosciences and Signature Therapeutics Company Profile

21:27 EDT 18th June 2019 | BioPortfolio

Ensysce, founded in Houston Texas, has an extensive carbon nanotube-related, worldwide intellectual property portfolio, including IP developed at Rice University by Dr. Smalley, at the University of Florida and Trinity College in Dublin, and issued patents of Ensysce for the use of SWCNT for therapeutic applications.


News Articles [1667 Associated News Articles listed on BioPortfolio]

Ensysce Biosciences to Present Novel TAAPTM and MPARTM Opioid Technology at SMi 19th Annual Pain Therapeutics Conference May 14, 2019

Ensysce Biosciences Inc., a clinical phase drug development company with innovative technologies to curb prescription drug abuse and overdose, today announced D. Lynn Kirkpatrick,...

Ensysce Biosciences Announces Key Additions to Executive Team Ahead of Financing

Ensysce is developing proprietary TAAPTM/MPARTM prodrug delivery and overdose technology to stem the opioid abuse epidemic Ensysce Biosciences Inc., a clinical pha...

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Genocea Biosciences on Top

Last week's top risers were Genocea Biosciences, Outlook Therapeutics, Hoth Therapeutics, Aveo Oncology and Evofem Biosciences. The post 5 Top Weekly NASDAQ Biotech and Pharma Stocks: Genocea Bioscien...

Seelos Therapeutics Announces Successful Completion of its Merger with Apricus Biosciences

Seelos Therapeutics (Nasdaq:SEEL), a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patient...

Caladrius Biosciences, Inc.: Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million

BASKING RIDGE, NJ / ACCESSWIRE / March 14, 2019 / Caladrius Biosciences, Inc. (NASDAQ: CLBS) ('Caladrius' or the 'Company'), a late-stage therapeutics development biopharmaceutical company committe...

Senolytic Therapeutics kicks off Q1 2019 with high-profile speaking events

(Life Biosciences) Senolytic Therapeutics, an innovator in senescent cell research and one of the first Daughter companies to join the hub-and-spoke business model of Life Biosciences, is being recogn...

RogCon Biosciences Launches with Late-Breaking Presentation on SCN2A Epilepsy at the 2018 AES ...

SAN DIEGO, Dec. 1, 2018 /PRNewswire/ -- RogCon Biosciences (RogCon), a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A Read more...

Neurocrine Biosciences and Voyager Therapeutics Form Development and Commercialization Collaboration for Parkinson’s Disease and Friedreich’s Ataxia

SAN DIEGO and CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR), today announced the formation of a str...

PubMed Articles [747 Associated PubMed Articles listed on BioPortfolio]

A short certificateless aggregate signature against coalition attacks.

Certificateless aggregate signature (CLAS) is a crucial cryptosystem. It can not only compress multiple signatures into a short signature, but also ensure the validity of each signature participating ...

An adhesion based approach for the detection of esophageal cancer.

Esophageal cancer has a 5 year survival rate of ∼20%. This dismal prognosis is due, in part, to the fact that esophageal cancer often presents at a late stage. Thus, there is a critical need for ass...

Toward Standardization of Mesenchymal Stromal Cell-Derived Extracellular Vesicles for Therapeutic Use: A Call for Action.

Extracellular vesicles (EVs), which include a variety of nano-sized membrane-encapsulated particles, are released to the extracellular microenvironment by the vast majority of cells and carry lipids, ...

A RNA sequencing-based six-gene signature for survival prediction in patients with glioblastoma.

Glioblastoma (GBM) is an aggressive tumor of the central nervous system that has poor prognosis despite extensive therapy. Therefore, it is essential to identify a gene expression-based signature for ...

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Clinical Trials [362 Associated Clinical Trials listed on BioPortfolio]

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis

Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as a possible treatment fo...

Validation of a Genetic Signature to Predict the Development of Sarcomas

The aim of the SARI study was to describe biomarkers of predisposition to the development of sarcomas in irradiated territory. This study included 120 patients with sarcoma in irradiated t...

Signature Personalised Patient Care System With the Vanguard Knee System Study

The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks i...

Xanthohumol Metabolism and Signature

A pilot study to assess the safety and tolerability of oral xanthohumol in humans, to identify a biological signature of xanthohumol exposure, and to characterize the role of xanthohumol m...

Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, s...

Companies [1801 Associated Companies listed on BioPortfolio]

Ensysce Biosciences and Signature Therapeutics

Ensysce, founded in Houston Texas, has an extensive carbon nanotube-related, worldwide intellectual property portfolio, including IP developed at Rice University by Dr. Smalley, a...

Ensysce Biosciences, Inc.

Ensysce Biosciences, San Diego, CA, is an integrated drug delivery company for both small and large molecules. To overcome the major problem of non-medical use of opioid products,...

Ensysce Biosciences Inc.

Ensysce Biosciences Inc. is focused on the use of carbon nanotubes for therapeutics in the area of cancer treatment. The company owns and has licensed an extensive carbon nanotube...

Signature Genomics

Signature Genomic Laboratories, founded in 2003, was the first laboratory to provide microarray-based cytogenetic diagnostics with its proprietary SignatureChip® and is the lea...

Signature Genomic Laboratories, LLC

Signature Genomic Laboratories, founded in 2003, was the first laboratory to provide microarray-based cytogenetic diagnostics with its proprietary SignatureChip® and is the lea...

More Information about "Ensysce Biosciences and Signature Therapeutics" on BioPortfolio

We have published hundreds of Ensysce Biosciences and Signature Therapeutics news stories on BioPortfolio along with dozens of Ensysce Biosciences and Signature Therapeutics Clinical Trials and PubMed Articles about Ensysce Biosciences and Signature Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ensysce Biosciences and Signature Therapeutics Companies in our database. You can also find out about relevant Ensysce Biosciences and Signature Therapeutics Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record